Category Archives: Regional News

You are here: Home » Category: "Regional News" (Page 2)

Neuralstem Reports Third Quarter 2018 Financial Results and Provides Business Update

– NSI-189 Received Orphan Designation for Treatment of Angelman Syndrome – – Initiated Phase 2 Clinical Trial of NSI-566 for Treatment of Chronic Stroke – – Second-Generation Neural Stem Cell Program NSI-532 Showed Positive Preclinical Results for Alzheimer’s Disease – – Closed $2.1 Million Registered Direct Offering –  GERMANTOWN, Md., Nov. 14, 2018 (GLOBE NEWSWIRE)…

[Read More]

Syneos Health Announces Corporate Leadership Positions

– NSI-189 Received Orphan Designation for Treatment of Angelman Syndrome – – Initiated Phase 2 Clinical Trial of NSI-566 for Treatment of Chronic Stroke – – Second-Generation Neural Stem Cell Program NSI-532 Showed Positive Preclinical Results for Alzheimer’s Disease – – Closed $2.1 Million Registered Direct Offering –  GERMANTOWN, Md., Nov. 14, 2018 (GLOBE NEWSWIRE)…

[Read More]

Helius Medical Technologies, Inc. Announces Proposed Public Offering of Class A Common Stock

– NSI-189 Received Orphan Designation for Treatment of Angelman Syndrome – – Initiated Phase 2 Clinical Trial of NSI-566 for Treatment of Chronic Stroke – – Second-Generation Neural Stem Cell Program NSI-532 Showed Positive Preclinical Results for Alzheimer’s Disease – – Closed $2.1 Million Registered Direct Offering –  GERMANTOWN, Md., Nov. 14, 2018 (GLOBE NEWSWIRE)…

[Read More]

Chiesi Salutes Neonatal Intensive Care Unit Staff in Honor of Prematurity Awareness Month®

– NSI-189 Received Orphan Designation for Treatment of Angelman Syndrome – – Initiated Phase 2 Clinical Trial of NSI-566 for Treatment of Chronic Stroke – – Second-Generation Neural Stem Cell Program NSI-532 Showed Positive Preclinical Results for Alzheimer’s Disease – – Closed $2.1 Million Registered Direct Offering –  GERMANTOWN, Md., Nov. 14, 2018 (GLOBE NEWSWIRE)…

[Read More]

Diffusion Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update

– NSI-189 Received Orphan Designation for Treatment of Angelman Syndrome – – Initiated Phase 2 Clinical Trial of NSI-566 for Treatment of Chronic Stroke – – Second-Generation Neural Stem Cell Program NSI-532 Showed Positive Preclinical Results for Alzheimer’s Disease – – Closed $2.1 Million Registered Direct Offering –  GERMANTOWN, Md., Nov. 14, 2018 (GLOBE NEWSWIRE)…

[Read More]

Virginia Premier Expands Engagement With the Inovalon One® Platform

– NSI-189 Received Orphan Designation for Treatment of Angelman Syndrome – – Initiated Phase 2 Clinical Trial of NSI-566 for Treatment of Chronic Stroke – – Second-Generation Neural Stem Cell Program NSI-532 Showed Positive Preclinical Results for Alzheimer’s Disease – – Closed $2.1 Million Registered Direct Offering –  GERMANTOWN, Md., Nov. 14, 2018 (GLOBE NEWSWIRE)…

[Read More]

Rexahn Pharmaceuticals Announces Leadership Transition

– NSI-189 Received Orphan Designation for Treatment of Angelman Syndrome – – Initiated Phase 2 Clinical Trial of NSI-566 for Treatment of Chronic Stroke – – Second-Generation Neural Stem Cell Program NSI-532 Showed Positive Preclinical Results for Alzheimer’s Disease – – Closed $2.1 Million Registered Direct Offering –  GERMANTOWN, Md., Nov. 14, 2018 (GLOBE NEWSWIRE)…

[Read More]

MacroGenics Announces Poster Presentation on Preclinical PD-L1 x CD137 DART® Program at the EORTC-NCI-AACR Symposium in Dublin

– NSI-189 Received Orphan Designation for Treatment of Angelman Syndrome – – Initiated Phase 2 Clinical Trial of NSI-566 for Treatment of Chronic Stroke – – Second-Generation Neural Stem Cell Program NSI-532 Showed Positive Preclinical Results for Alzheimer’s Disease – – Closed $2.1 Million Registered Direct Offering –  GERMANTOWN, Md., Nov. 14, 2018 (GLOBE NEWSWIRE)…

[Read More]

Recro Pharma Announces Publication of Phase II IV Meloxicam Abdominal Hysterectomy Data in Anesthesia & Analgesia

– NSI-189 Received Orphan Designation for Treatment of Angelman Syndrome – – Initiated Phase 2 Clinical Trial of NSI-566 for Treatment of Chronic Stroke – – Second-Generation Neural Stem Cell Program NSI-532 Showed Positive Preclinical Results for Alzheimer’s Disease – – Closed $2.1 Million Registered Direct Offering –  GERMANTOWN, Md., Nov. 14, 2018 (GLOBE NEWSWIRE)…

[Read More]

Novan Phase 2 Molluscum Contagiosum Trial Achieves Statistical Significance in Preliminary Top Line Results

– NSI-189 Received Orphan Designation for Treatment of Angelman Syndrome – – Initiated Phase 2 Clinical Trial of NSI-566 for Treatment of Chronic Stroke – – Second-Generation Neural Stem Cell Program NSI-532 Showed Positive Preclinical Results for Alzheimer’s Disease – – Closed $2.1 Million Registered Direct Offering –  GERMANTOWN, Md., Nov. 14, 2018 (GLOBE NEWSWIRE)…

[Read More]